Biotech Act must deliver, not become a ‘paper monster’, says Belgian MEP Beke

EURACTIV - Speeding up clinical trials must be a central test of the EU's proposed Biotech Act, as Europe risks forfeiting the economic returns on its own scientific breakthroughs, Belgian MEP Wouter Beke has warned.  Read more

Belgian MEP, co-rapporteur in the European Parliament's industry committee (ITRE) on the Biotech Act, Wouter Beke [Photo Credit: European Parliament]